Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like V*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068011304 Iloperidone 1 & 2 & 4 & 6 MG Tablet 8 EA 07/16/2022 18.32 233.84 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068010102 Iloperidone 1 MG Tablet 60 EA 07/16/2022 137.38 1753.63 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068011002 Iloperidone 10 MG Tablet 60 EA 07/16/2022 270.71 3455.52 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068011202 Iloperidone 12 MG Tablet 60 EA 07/16/2022 270.71 3455.52 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068010202 Iloperidone 2 MG Tablet 60 EA 07/16/2022 137.38 1753.63 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068010402 Iloperidone 4 MG Tablet 60 EA 07/16/2022 137.38 1753.63 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068010602 Iloperidone 6 MG Tablet 60 EA 07/16/2022 169.04 2157.74 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068010802 Iloperidone 8 MG Tablet 60 EA 07/16/2022 169.04 2157.74 12/28/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068022001 Tasimelteon 20 MG Capsule 30 EA 07/16/2022 1865.22 23808.98 08/29/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068030406 Tasimelteon 4 MG/ML Suspension 158 ML 07/16/2022 1964.70 25078.79 12/11/2040 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000098 Vanda Pharmaceuticals Inc. 09/30/2022 43068030402 Tasimelteon 4 MG/ML Suspension 48 ML 07/16/2022 596.87 7618.87 12/11/2040 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000416 Veloxis Pharmaceuticals, Inc. 12/31/2022 68992307501 Envarsus XR .75mg 100 Tab 12/23/2022 16.10 475.88 08/30/2028 Single Source Drug 31741 None None 1 None 1 None None None None None None None None None None None
Rx0000416 Veloxis Pharmaceuticals, Inc. 12/31/2022 68992307503 Envarsus XR .75mg 30 Tab 12/23/2022 4.83 142.77 08/30/2028 Single Source Drug 54789 None None 1 None 1 None None None None None None None None None None None
Rx0000416 Veloxis Pharmaceuticals, Inc. 12/31/2022 68992301001 Envarsus XR 1mg 100 Tab 12/23/2022 21.46 634.51 08/30/2028 Single Source Drug 159730 None None 1 None 1 None None None None None None None None None None None
Rx0000416 Veloxis Pharmaceuticals, Inc. 12/31/2022 68992301003 Envarsus XR 1mg 30 Tab 12/23/2022 6.44 190.36 08/30/2028 Single Source Drug 231804 None None 1 None 1 None None None None None None None None None None None
Rx0000416 Veloxis Pharmaceuticals, Inc. 12/31/2022 68992304001 Envarsus XR 4mg 100 Tab 12/23/2022 85.84 2538.00 08/30/2028 Single Source Drug 47258 None None 1 None 1 None None None None None None None None None None None
Rx0000416 Veloxis Pharmaceuticals, Inc. 12/31/2022 68992304003 Envarsus XR 4mg 30 Tab 12/23/2022 25.76 761.40 08/30/2028 Single Source Drug 82394 None None 1 None 1 None None None None None None None None None None None
Rx0000450 Vericel Corporation 12/31/2022 69866103005 MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3) 10/01/2022 3646.00 52252.00 11/25/2033 Single Source Drug None 1 The Company is implementing this price increase to account for inflation and mitigate its rising cost of goods including the increased costs of materials from suppliers. None No improvement. None None None None None None None None None None None Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021.
Rx0000450 Vericel Corporation 12/31/2022 69866103008 MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX (69866-1030-8) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) 10/01/2022 7292.00 104504.00 11/25/2033 Single Source Drug None 1 The Company is implementing this price increase to account for inflation and mitigate its rising cost of goods including the increased costs of materials from suppliers. None No improvement. None None None None None None None None None None None Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000450 Vericel Corporation 06/30/2022 69866103008 MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) 06/17/2022 34664.00 97212.00 11/25/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025005230 Corvite 150 30 CT 09/03/2022 11.96 161.41 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025006030 Corvite Fe 30 CT 09/03/2022 15.73 212.31 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025006530 Divigel 0.1% 0.25 mg 09/03/2022 6.57 168.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025006630 Divigel 0.1% 0.5 mg 09/03/2022 6.57 168.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025008330 Divigel 0.1% 0.75 mg 09/03/2022 6.57 168.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025006730 Divigel 0.1% 1.0 mg 09/03/2022 6.57 168.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025008630 Divigel 0.1% 1.25 mg 09/03/2022 6.57 168.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025001010 OB Complete 100 CT 09/03/2022 20.76 280.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025004960 OB Complete DHA 60 CT 09/03/2022 16.38 220.28 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025004430 OB Complete One 30 CT 09/03/2022 16.61 224.23 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025005930 OB Complete Petite 30 CT 09/03/2022 16.82 227.01 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000155 Vertical Pharmaceuticals, LLC 09/30/2022 68025004330 OB Complete Premier 30 CT 09/03/2022 11.64 157.15 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Developed by Vertical
Rx0000414 Vifor Pharma Inc. 06/30/2022 53436008404 Veltassa® (patiromer sorbitex calcium powder), for oral suspension 4 packets 8.4 grams 04/01/2022 4.20 172.10 10/08/2033 Single Source Drug None 1 Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive. None None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=660 None
Rx0000414 Vifor Pharma Inc. 06/30/2022 53436016830 Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 16.8 grams 04/01/2022 23.56 965.92 10/08/2033 Single Source Drug None 1 Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive. None None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=662 None
Rx0000414 Vifor Pharma Inc. 06/30/2022 53436025230 Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 25.2 grams 04/01/2022 23.56 965.92 10/08/2033 Single Source Drug None 1 Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive. None None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=663 None
Rx0000414 Vifor Pharma Inc. 06/30/2022 53436008430 Veltassa® (patiromer sorbitex calcium powder), for oral suspension Veltassa® (patiromer sorbitex calcium powder), for oral suspension 30 packets 8.4 grams 04/01/2022 23.56 965.92 10/08/2033 Single Source Drug None 1 Vifor bases pricing decisions, including price changes, on a range of market and business considerations including market dynamics, the competitive environment, inflationary costs associated with manufacturing, storage and supply, ongoing pharmacovigilance, and other factors. Vifor sets prices to reflect the value of our medicines to patients and society, enabling us to remain competitive. None None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=661 None